CAR-T Therapy Overview

  • ID: 4375352
  • Drug Pipelines
  • iOnco-analytics
1 of 4
Ideal for Those Wishing to Gain an Up-to-Date Understanding of the CAR-T Landscape

FEATURED COMPANIES

  • Bluebird bio
  • Celgene Corporation
  • Celyad
  • Juno Therapeutics Inc
  • Kite Pharma
  • Novartis
  • MORE

This report consists of a detailed Executive presentation (~91 slides) and MS-Excel work book summarizing latest developments in CAR-T therapies with a full review of the field to date. A searchable database of nearly 200 CAR trials has been compiled with analysis by start date, current phase, indication and sponsor type (industry and/or academic). For the hematological cancers, detailed case studies are provided looking at clinical trial parameters and data presented to date. Future perspectives, key risks, and challenges along with summary and conclusions are provided. This analysis is ideal for those wishing to gain an up-to-date understanding of the CAR-T landscape.

CAR-T or Chimeric Antigen Receptor T cells are a sub component of Adoptive T Cell therapy (ACT), a promising new treatment intervention for cancer. In ACT, a patient’s individual T cells are removed and manipulated so they have an increased capacity to fight cancer. The therapy is usually personalized (autologous) for a specific patient.

Chimeric antigen receptor T cells present hybrid receptors consisting of an antigen binding domain of an antibody (e.g. directed to CD19) fused to the T-cell receptor signalling domain. So far, the technology has undergone four generations of development, where second-generation approaches have shown remarkable responses in clinical studies. Complete remission in up to 90% of patients have been reported for relapsed or refractory B-cell Acute Lymphoblastic Leukaemia (B-ALL). Since 2015/2016 commercial interest has heightened in the development of CAR-T therapies with companies involved in clinical studies, mainly against hematological cancers.

*** Please allow up to 48 hours for this product to be dispatched ***

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bluebird bio
  • Celgene Corporation
  • Celyad
  • Juno Therapeutics Inc
  • Kite Pharma
  • Novartis
  • MORE
  • Executive summary
  • Chimeric Antigen Receptors (CAR) – Background
  • Cancer Immunotherapy
  • Adoptive T cell therapy - T cells
  • Categories of adoptive T cell therapies
  • Adoptive T cell therapy - TIL approach
  • Adoptive T cell therapy - Genetically modified T cell approach
  • Adoptive T cell therapy - Genetically modified T cell approach - Engineered T cell receptor
  • Adoptive T cell therapy - Genetically modified T cell approach - Chimeric Antigen Receptor T cells (CAR-T)
  • Adoptive T cell therapy - Antigen selection for a CAR-T approach
  • CAR-T cell therapy - Potential issues and challenges
  • Chimeric Antigen Receptor T cells (CAR-T) - Review of Key Successful Clinical Trials
  • CAR-T cell therapy - successful clinical trials for CD19-CAR-T targeting acute lymphoblastic leukaemia
  • CAR-T cell therapy - successful clinical trials for CD19-CAR-T targeting lymphoma
  • Chimeric Antigen Receptors (CAR) - Current R&D pipeline
  • CAR-T Therapy - pipeline analysis methodology
  • Chimeric Antigen Receptor (CAR) Trials: total number of clinical trials
  • Chimeric Antigen Receptor (CAR) Trials: activity 2008-present
  • Chimeric Antigen Receptor (CAR) Trials: activity (industry)
  • Chimeric Antigen Receptor (CAR) Trials: activity (non industry)
  • Chimeric Antigen Receptor (CAR) Trials: phases and sponsor type
  • Chimeric Antigen Receptor (CAR) Trials: target indications (all phases)
  • Chimeric Antigen Receptor (CAR) Trials: phase I-IV, by indication
  • Chimeric Antigen Receptor (CAR) Trials: haematological indications, phases and sponsor type
  • Chimeric Antigen Receptor (CAR) Trials: multiple indications - phases and sponsor type
  • Chimeric Antigen Receptor (CAR) Trials: neurological indications - phases and sponsor type
  • Chimeric Antigen Receptors (CAR) - Advanced Clinical Trials for Blood Cancer Targets: Leukaemia/Lymphoma/Myeloma
  • Chimeric Antigen Receptor (CAR) Trials - haematological cancer targets
  • Blood cancer targets for CAR-T therapy: Leukaemia (background)
  • Leukaemia: survival rates and treatment types
  • Blood cancer targets for CAR-T therapy: Lymphoma (background) and survival rates
  • Lymphoma: current treatments
  • Blood cancer targets for CAR-T therapy: Myeloma (background), survival rates and current treatments
  • Advanced Clinical Trials for Leukaemia/Lymphoma/Myeloma
  • Leukaemia/Lymphoma/Myeloma - Industry sponsored CAR-T studies
  • Chimeric Antigen Receptors (CAR) - In depth review of key industry sponsored programmes
  • Bluebird bio, Celgene Corporation: BB2121
  • Cellular Biomedicine Group Ltd: C-CAR011
  • Celyad: NKR2
  • Juno Therapeutics Inc, Celgene Corporation: JCAR017
  • Juno Therapeutics Inc, Celgene Corporation: other CD19+ trials
  • Juno Therapeutics Inc: CAR-T trials for additional targets
  • Juno Therapeutics, Inc., MedImmune LLC: JCAR014
  • Takara Bio Inc
  • Kite Pharma: KTE-C19
  • Novartis: CTL019
  • Novartis: CD19 CAR-T Long Term Follow Up
  • Servier, Cellectis, Pfizer: UCART19
  • Cellectis: additional UCARTS
  • CAR-T - summary and conclusions
  • Bibliography
  • About us
  • Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bluebird bio
  • Celgene Corporation
  • Cellular Biomedicine Group Ltd
  • Celyad
  • Juno Therapeutics Inc
  • Kite Pharma
  • Novartis
  • Pfizer
  • Servier
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll